BIOMX

Company Snapshot

Founded: 2015
Entity Type: Public
Employees: 20
Region: Israel
Headquarter: Ness Ziona, Israel
Key Geographics: U.S., Israel
Corporate Address: 22 Einstein Street, Floor 4, Ness Ziona, 7414003 Israel Tel. +972-7239-42377 www.biomx.com

Company Overview

BiomX is a microbiome company working towards the development of phage-based therapies. BiomX is developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

The technology of BiomX relies on finding the best suited phage and using synthetic biology approaches to engineer these phages. The phage cocktail is then optimized in vitro and in vivo for the best activity.

BiomX has several partnerships for the development of microbiome therapeutics:

  • BiomX exclusively licensed the access to phage discovery systems and the target bacteria discovery platform from the Weizmann Institute of Science, Israel.
  • In collaboration with Takeda, BiomX is developing formulations for its phage therapy manufacturing intermediates and for the final form to be administered.
  • BiomX exclusively sub-licensed a set of bacterial targets for the development of phage therapies for the treatment of IBD from JSR Corp.
  • In collaboration with Janssen Pharmaceuticals Inc., BiomX is using its XMarker microbiome-based biomarker discovery platform to stratify responders and non-responders to IBD therapeutics.

In Sept. 2020, BiomX entered into a collaboration with Boehringer Ingelheim to use the BiomX XMarker microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in IBD.

In Oct. 2021, the company entered into a stock purchase agreement with a subsidiary of Maruho Co. Ltd., a leading dermatology focused pharmaceutical company in Japan, pursuant, to which, the Company issued to Maruho 375,000 shares of common stock at a price of $8.00 per share for gross proceeds of $3,000. The company granted Maruho a right of first offer to license its atopic dermatitis product candidate, BX005, in Japan.

In June 2021, a second partnership between Boehringer Ingelheim and BiomX is focused on inflammatory bowel disease (IBD). Using the XMarker discovery platform from Israel-based BiomX, the two businesses will collaborate to find the disease's biomarkers.

BIOMX In Reports

Microbiome Therapeutics: Global Markets

Global market for microbiome therapeutics is estimated to increase from $164.8 million in 2022 to reach $1.5 billion by 2027, at a CAGR of 54.8% from 2022 through 2027.

Synthetic Biology: Global Markets

BCC Research Market Report for synthetic biology is estimated to increase from $9.5 billion in 2021 to $33.2 billion by 2026, at a compound annual growth rate of 28.4%

Microbiome Therapeutics: Global Markets

BCC Research’s new report, “Microbiome Therapeutics: Global Markets,” provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2025. ...

Company's Business Segments

  • Product : BX004, BX211/BX011, Bolt, Xmarker
  • Service : Analysis, Research and Development, Clinical Support

Applications/End User Industries

  • Healthcare
  • Pharmaceuticals
  • Biotechnology
AI Sentiment